Abstract
This study leverages X-ray phase-contrast tomography for detailed analysis of neurodegenerative diseases focusing on the 3D visualization and quantification of neuropathological features within fixed human postmortem tissue. X-ray phase-contrast tomography with synchrotron radiation offers micrometer and even sub-micron resolution, enabling us to examine intra- and extraneuronal aggregates and inclusions such as Lewy bodies, granulovacuolar degeneration, Hirano bodies, neurofibrillary tangles, β-amyloid plaques and vascular amyloid deposits in three dimensions (3D). In the reconstructions, we identified the highest electron densities in Hirano bodies and Lewy bodies while neurofibrillary tangles exhibit only slight alterations in X-ray phase-contrast tomography contrast. Using cutting edge high-resolution X-ray synchrotron beamlines we are now able to even detect subcellular differences of electron densities found in granulovacuolar degeneration. Small scale inhomogeneities of the electron density are also detected in Lewy bodies potentially relating to inclusions of organelles. Additionally, we reveal a peculiar 3D geometry of Hirano bodies and demonstrate the co-occurence with granulovacuolar degeneration in the same neuron. Utilizing X-ray phase-contrast tomography in a complementary fashion to traditional technologies, a quantitative, systematic and disease-overarching understanding of inclusions and aggregates in neurodegeneration can be achieved.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project ID 432680300: SFB 1456/A03 (Mathematics of Experiment) and under Germany`s Excellence Strategy: EXC 2067/1 390729940. This research was funded in part by Aligning Science Across Parkinson`s ASAP-020625 through the Michael J. Fox Foundation for Parkinson's Research (MJFF). JF was supported by the UMG Clinician Scientist Program. JR was supported by the Hertha Sponer College (MBExC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval and consent to participate} Brain tissue blocks of patients with neurodegenerative diseases were obtained during diagnostic autopsy and retrieved from the archives of the Institute of Neuropathology, University Medical Center Goettingen, Germany. The tissue was used in an anonymized fashion. The study was approved by the ethics committee of the University Medical Center Goettingen (22/1/19).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The title was updated and a general revision of the text, in particular regarding the results and the discussion sections, was conducted. Author affiliations were updated, as well as the supplemental files.
Data Availability
Raw data were generated at ESRF and DESY. Raw data will be released and made public two years after the beamtime. All treated datasets are available from the corresponding author on request. Exemplary datasets that support the findings of this study will be openly available in GRO.data upon publication.
